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The interaction of glucagon-like peptide-l (7-36)amide (GLP-1) and glucose-dependent i sulin-releasing polypeptide 
(GIP) on insulin release from the perfused rat pancreas was studied. The GLP-1 stimulated (0.5 nmol/l), glucose-induced 
(6.7 mmol/l) insulin secretory answer was enhanced by GIP (0.1, 1.0 and 10.0 nmol/l) to the arterial perfusate. This effect 
was maximal at 1 nmol/l GIP and smaller but still significant at 0.1 nmol/l GIP. The high GIP concentration of 10 nmol/l 
GIP did not further increase insulin secretion compared to the stimulation by 1 nmol/l GIP. Our data demonstrate an 
additive synergistic effect of GLP-1 and GIP on the glucose-induced insulin release. This supports the concept of an action 
‘in concert’ of gastrointestinal incretin hormones postprandially released on the endocrine pancreas to guarantee ade- 
quate insulin answers after meals. 
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1. INTRODUCTION 
It is believed that hormones released from the 
gastrointestinal tract exert an influence upon the 
secretion of pancreatic islet cell hormones [ 11. The 
physiological function of such an ‘entero-insular 
axis’ would be to augment or modify the islet cell 
hormone responses to ingested substrates [2]. In- 
cretin hormones, one part of this system, refer to 
the endocrine factors liberated from the gut which 
potentiate the insulin response to oral ingestion of 
food [l]. Previously, since it acts as potent insulin 
secretagogue GIP was the leading candidate for a 
physiological relevant incretin [3]. However, 
strong evidence from various studies suggested 
that additional factors are of importance to fully 
explain the incretin effect [4,5]. Recent studies 
claim the proglucagon derived glucagon-like 
peptide-l (7-36)amide (GLP-1) to represent an 
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important, powerful incretin hormone in animals 
and humans [6-9,241. The current study was 
undertaken to examine the possible interaction of 
GIP and GLP-1 on insulin secretion. This was of 
interest since previous studies showed that func- 
tional interactions of different gut hormones at the 
pancreatic B-cell are of significance in regulating 
the insulin response to achieve adequate postpran- 
dial insulin answer [lo, 111. 
2. MATERIALS AND METHODS 
2.1. Substances 
Synthetic GLP-1 and GIP were purchased from Peninsula 
(St. Helens, Merseyside). Bovine serum albumin (fraction V) 
was from Serva (Heidelberg, FRG) and aprotinin (Trasylol) 
from Bayer (Leverkusen, FRG). All other chemicals used were 
of analytical grade and were purchased from Merck (Darm- 
stadt, FRG). 
2.2. Animals 
Male albino Wistar rats (180-240 g) kept in a light and 
temperature controlled room were fed a standard diet 
(Altromin, Lage, FRG) and had free access to water ad libitum. 
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Fig. 1. Effect of GIP (0.1, 1, 10 nmol/l) on glucose (6.7 mmol/l)-induced and GLP-1 (0.5 nmol/l)-stimulated insulin secretion from 
the isolated perfused rat pancreas. (I) Glucose + GLP-1; (II) glucose + GLP-1 + GIP (0.1 nmol/l); (III) glucose + GLP-1 + GIP 
(1 nmol/l); (IV) glucose + GLP-1 + GIP (10 nmol/l). 
2.3. Perfusion experiments 
Rats were anesthetized by an intraperitoneal injection of pen- 
tobarbitone sodium (45 mg/kg body wt). The pancreas, spleen, 
stomach, and proximal part of the duodenum were perfused 
through the cannulated abdominal aorta as described previous- 
ly [ 121. The entire preparation was removed from the cadaver 
and placed into a perfusion chamber. The perfusion media con- 
sisted of a Krebs-Henseleit bicarbonate buffer (pH 7.4 when 
gassed with 95% 0 and 5% CO) as was detailed before 120). 
The venous effluent was collected on aprotinin (1000 Wfrac- 
tion) in intervals by a cannula inserted into the portal vein. The 
perfusion pumps were adjusted to generate aconstant flow rate 
Table 1 
Effect of glucagon-like peptide-l (7-36)amide and GIP on insulin secretion from 
the isolated perfused rat pancreas 
Glucose 
(mM) 
GLP-1 GIP n First phase Second phase 
(nM) (nM) (O-S min) (9-44 min) 
6.7 
6.7 
6.7 
6.7 
6.7 
6.7 
6.7 
6.7 
_ - 7 25.7 + 10.1 
0.5 - 6 68.1 rt 11.8a 
0.5 0.1 6 51.2 k 24.8 
0.5 1 6 77.0 k 20.4’ 
0.5 10 6 77.6 -+ 10.5’ 
_ 0.1 5 30.7 + 10.0 
_ 1 6 30.6 f 6.7 
- 10 6 46.5 + 9.2” 
100.9 + 43.8 
248.6 f 164.5” 
385.6 + 37 Obc 
439.6 + 43:7bC 
444.9 + 67.Sbc 
137.2 + 37.7 
157.7 + 20.6 
208.0 & 29.9a 
a Significantly different integrated insulin secretion rate compared to controls 
(sole glucose, p < 0.05) 
b Significantly different integrated insulin secretion rate compared to experiments 
with glucose and GLP-1 @ < 0.05) 
’ Significantly different integrated insulin secretion rate compared to experiments 
with glucose and GIP @ < 0.05) 
Given are means f SE of (n) experiments 
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Fig.2. Effect of 0.1, 1 and 10 nmol/l GIP on glucose (6.7 mmol/l)-induced insulin secretion from the isolated perfused rat pancreas. 
(I) Glucose; (II) glucose + 0.1 nmol/l GIP; (III) glucose + 1 nmol/l GIP; (IV) glucose + 10 nmol/l GIP. 
of 4 ml/min. One perfusion experiment lasted for 54 min. 
After a basal period of 10 min for equilibration (2.8 mmol/l 
glucose) the glucose concentration was raised to 6.7 mmol/l 
glucose. Under the latter condition the effect of GIP’(O.l, 1.0 
and 10 nmol/l) on the glucose-induced (6.7 mmol/l) and 
GLP-1 (0.5 nmol/l) stimulated insulin was investigated. Insulin 
was measured by radioimmunoassay [ 131. The standard was a 
mixture of rat insulin I and II and was obtained from Novo 
(Mainz, FRG). Integrated insulin secretion was determined as 
secretion rate of the first (ng insulin/O-8 min) and the second 
phase (ng insulin/9-44 min) of the biphasic insulin answer 
from the perfused rat pancreas. 
2.4. Statistics 
Statistical analysis was performed by the U-test. Statistical 
significance was set at the 5% level. 
3. RESULTS 
After perfusion of the pancreata by media con- 
taining glucose (6.7 mmol/l) or glucose plus 
GLP-1 (0.5 nmol/l) a typical biphasic pattern of 
the insulin answer was observed (fig.1). The 
GLP-1 concentration considered in the present ex- 
periments exerted a significant but weak 
stimulatory effect on insulin secretion (fig. 1). This 
finding corroborates recent reports describing the 
dose-response relationship between GLP-1 
stimulation and insulin release from the perfused 
pancreas [7,14,15]. 0.5 nmol/l GLP-I increased 
the glucose-induced insulin release in both the first 
and the second phase of the secretory insulin 
response compared to glucose stimulation of secre- 
tion alone (fig.2, table 1). GIP in our hands show- 
ed a glucose- and concentration-dependent 
insulinotropic action as was described before 
[15,16]. The combination of GLP-1 (0.5 nmol/l) 
and GIP revealed an additive, synergistic effect on 
insulin release (fig.1, table 1). This effect was 
dependent on the GIP concentration used. In the 
presence of 0.5 nmol/l GLP-1 this effect was max- 
imal at 1 nmol/l GIP and smaller but still signifi- 
cant at 0.1 nmol/l GIP (table 1). The effect was 
not further enhanced at the higher GIP concentra- 
tion of 10 nmol/l GIP. The synergistic interaction 
of both hormones on insulin release was more pro- 
nounced on the second phase of the secretory 
answer (table 1). 
4. DISCUSSION 
It is believed that the nutrient-dependent release 
of gut hormones is of significance in the regulation 
of endocrine pancreatic function [2]. Strong 
evidence exists now that this regulation is 
facilitated by interactions of various incretin fac- 
tors [lo, 111. It was of special interest to study the 
interaction of GIP and GLP-1 on insulin release. 
GIP until recently, played a unique role as incretin 
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candidate, and GLP-1 is now a promising new can- 
didate peptide for the modulation of insulin secre- 
tion in response to carbohydrates [6-9,141. 
In a recent study Zawalich reported that the 
combination of GIP plus cholecystokinin (CCK) 
together with 7 mmol/l glucose induced a marked- 
ly amplified insulin response from rat perifused 
islets [ll]. Ahren et al. [lo] demonstrated 
previously that GIP and CCK-8 in low doses 
possess trong insulinotropic activity when injected 
together in mice. It is known that GIP facilitates 
the glucose-induced insulin output by elevating 
islet CAMP [17]. Furthermore, CCK, via the 
phosphoinositides, generates at least several se- 
cond messengers in islets [ll]. Therefore, it was 
suggested that CCK and GIP modulate the levels 
of separate second messengers and that their 
synergistic impact on insulin secretion might be ex- 
plained by these separate actions on those second 
messenger systems [ 111. 
Recently, we have shown that the GLP-1 
stimulated, glucose-induced insulin release is 
strongly potentiated by addition of CCK-8 [ 19,201. 
Since the signal transmission after binding of 
GLP-1 to B-cells is adenylate-cyclase linked 
[21-231, we have explained the CCK potentiation 
of the GLP-1 effect on insulin by a synergistic in- 
teraction of the different second messenger 
systems as was suggested by Zawalich in the case of 
GIP and CCK. Our present results indicate an ad- 
ditive effect of GLP-1 and GIP on insulin secre- 
tion. This effect was maximal at 1 nmol/l GIP and 
was not further enhanced at the higher GIP con- 
centration. However, when the glucose-induced in- 
sulin secretion was stimulated by GIP alone (fig.2) 
the resulting insulin release was stronger in 
response to 10 nmol/l GIP compared to the lower 
concentration of 1 nmol/l. Since both hormones, 
GIP and GLP-1, act via the adenylate cyclase 
system the combination of both seems to result in 
only an additive effect. It seems likely, that the in- 
teraction of lower, i.e. respectively submaximal, 
effective concentrations of GIP and GLP-1 could 
result in the full CAMP answer in the B-cell which 
is not further increased by higher amounts of the 
individual hormones. In conclusion, our data sug- 
gest an additive effect of GLP-1 and GIP on the 
glucose-induced insulin release from the perfused 
pancreas. This supports the concept of an existence 
of several incretin factors in the enteroinsulinar 
112 
axis with functional interactions on the pancreatic 
B-cell level. 
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